
    
      This is a phase III,Multi-center,prospective,randomized clinical trials. The objective
      compare the efficacy of bicalutamide with conventional chemotherapy (Treatment of Physician's
      Choice,TPC) in first-line treatment of AR positive metastatic triple negative breast
      cancer.Primary endpoint is 16-week clinical benefit rate (CBR).By centre randomized grouping
      bicalutamide (experimental Group) or TPC (Control Group).
    
  